Immunic, Inc. (IMUX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Immunic, Inc. (IMUX)
Go deeper and ask any question about IMUX
Company Performance
Current Price
as of Sep 13, 2024$1.52
P/E Ratio
N/A
Market Cap
$136.92M
Description
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerIMUX
- Price$1.52+2.01%
Trading Information
- Market Cap$136.92M
- Float94.67%
- Average Daily Volume (1m)289,453
- Average Daily Volume (3m)313,056
- EPS-$1.51
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$21.38M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$22.78M
- EV$33.67M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account